In the phase II trial, rilotumumab showed some anti-tumor efficacy in gastric and gastroesophageal cancer.598 Unfortunately, in the pivotal phase III RILOMET-1 trial, the addition of rilotumumab to chemotherapy failed to improve the outcome of gastric and gastroesophageal cancer.599 Currently, research on c-MET inhibitor drugs mainly focuses on tyrosine kinase inhibitors. This evidence concerns the gene MET and neoplasm.